FEMY: Femasys Corporation Projected Price to Earnings

Is it worth investing in Femasys Inc. (FEMY), given the diversification of its infertility treatment solutions? The forward P/E dynamics of the issuer on the GURU.Markets chart provide the answer, where the 0.00 mark serves as the current indicator. Gynecologists value the brand for its high-precision, minimally invasive diagnostic systems. Currently, growth is driven by active sales of the innovative FemaSeed system in US clinics.

FEMY - Femasys Market Cap to Projected Earnings over the range 07/04/2022 - 11/14/2026

Analytical breakdowns and data insights for company Femasys Corporation (FEMY)

- stock value and consensus price forecast:

Price Chart Femasys|FEMY - Price Target Chart

- market capitalization information:

Market Valuation Femasys Inc|FEMY - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Femasys|FEMY - Book Valuation of Business|Market Value to Book Value Ratio femasys.com|FEMY - Total Business Assets

- debt burden and liquidity indicators:

- earnings and market ratios statistics:

FEMY - Net Income|Projected Future Earnings Femasys Inc.|FEMY - Market Cap to Earnings|Future Price to Earnings Femasys Corp|FEMY - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Femasys Inc|FEMY - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months Femasys|FEMY - Net earnings per share for the last four quarters|Quarterly EPS earnings growth femasys.com|FEMY - Earnings per share trend in current year|Earnings growth forecast for next year Femasys Inc.

- revenue and sales proceeds data:

FEMY - Company Total Revenue|Company Projected Revenue Femasys|FEMY - Market Cap to Revenue|Forward P/S Multiple Femasys Inc

Summary company analysis:FEMY Femasys

The forward P/E reflects the business value relative to expected net income, allowing investors to assess the premium paid for future earnings per share. By analyzing the forward P/E multiple of the business, the market determines the fair value of Femasys Inc. (FEMY) assets, accounting for the commercialization potential of their contraception systems and diagnostic devices for infertility treatment.

Direct competitors